Anzeige
Erschienen in:
01.03.2016 | Original Article
Stereotactic intracavitary brachytherapy with P-32 for cystic craniopharyngiomas in children
Erschienen in: Strahlentherapie und Onkologie | Ausgabe 3/2016
Einloggen, um Zugang zu erhaltenAbstract
Purpose
Although microsurgery remains the first-line treatment, gross total resection of cystic craniopharyngeomas (CP) is associated with significant morbidity and mortality and the addition of external irradiation to subtotal resection proves to achieve similar tumor control. However, concern regarding long-term morbidity associated with external irradiation in children still remains. With this retrospective analysis, the authors emphasize intracavitary brachytherapy using phosphorus-32 (P-32) as a treatment option for children with cystic CP.
Patients and methods
Between 1992 and 2009, 17 children (median age 15.4 years; range 7–18 years) with cystic CP underwent intracavitary brachytherapy using P-32. Eleven patients were treated for recurrent tumor cysts; 6 patients were treated primarily. MR imaging revealed solitary cysts in 7 patients; 10 patients had mixed solid–cystic lesions (median tumor volume 11.1 ml; range 0.5–78.9 ml). The median follow-up time was 61.9 months (range 16.9–196.6 months).
Results
Local cyst control could be achieved in 14 patients (82 %). Three patients showed progression of the treated cystic formation (in-field progression) after a median time of 8.3 months (range 5.3–10.3 months), which led to subsequent interventions. The development of new, defined cysts and progression of solid tumor parts (out-of-field progression) occurred in 5 patients and led to additional interventions in 4 cases. There was neither surgery-related permanent morbidity nor mortality in this study. The overall progression-free survival was 75, 63, and 52 % after 1, 3, and 5 years, respectively.
Conclusion
Intracavitary brachytherapy using P-32 represents a safe and effective treatment option for children harboring cystic CP, even as primary treatment. However, P-32 does not clearly affect growth of solid tumor parts or the development of new cystic formations.